FindTrial
Sign In

PhaseII/III double-blind comparative study of the efficacy and safety of TAK-536CCB when coadministered with hydrochlorothiazide in patients with grade I or II essential hypertension

-

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221917
Enrollment
Unknown
Registered
2012-09-13
Start date
2012-09-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

investigational material(s) Generic name etc : TAK-536CCB,HCTZ INN of investigational material : Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational materi

Sponsors

TAKEDA PHARMACEUTICAL COMPANY LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Grade I or II essential hypertension. - At both Week -2 and Week 0, sitting blood pressure (measured in the examination room) satisfied the following criteria: Systolic blood pressure: >=150 mmHg and =95 mmHg and <110 mmHg, etc.

Exclusion criteria

Exclusion criteria: Secondary hypertension, malignant hypertension or grade III hypertension. Significant "white-coat hypertension" Sleep apnea syndrome requiring treatment Clinically defined hepatic disorder Clinically defined renal disorder Significantly low or high levels of K or Na in body fluids, etc.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026